FRISCO, Texas / Mar 11, 2025 / Business Wire / Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, today announced that Dirk Allison, Chairman and Chief Executive Officer, Brad Bickham, President and Chief Operating Officer, and Brian Poff, Executive Vice President and Chief Financial Officer, will participate in the following investor conferences:
In connection with the virtual conferences, there will be a live broadcast and replay of the Company’s presentation available under the Investor Relations section of the Company’s website, www.addus.com. An online replay will also be available on the Company’s website for one month, beginning approximately one hour following the conclusion of the live broadcast.
About Addus HomeCare
Addus HomeCare is a provider of home care services that primarily include personal care services that assist with activities of daily living, as well as hospice and home health services. Addus HomeCare’s consumers are primarily persons who, without these services, are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. Addus HomeCare’s payor clients include federal, state, and local governmental agencies, managed care organizations, commercial insurers, and private individuals. Addus HomeCare currently provides home care services to approximately 62,000 consumers through 257 locations across 23 states. For more information, please visit www.addus.com.
Last Trade: | US$100.41 |
Daily Change: | 1.17 1.18 |
Daily Volume: | 192,013 |
Market Cap: | US$1.820B |
November 04, 2024 August 05, 2024 June 28, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load